Table 1 Baseline patient characteristics and their association with TTR and OS in univariate analysis

From: A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients

    TTR OS
Parameter n % HR (95% CI) P -value HR (95% CI) P -value
Gender
 Male 217 58.3 1 (reference) 0.417 1 (reference) 0.801
 Female 155 41.7 1.19 (0.80–1.79)   1.06 (0.66–1.70)  
Tumour location
 Left 130 34.9 1 (reference) 0.781 1 (reference) 0.273
 Right 242 65.1 1.06 (0.69–1.63)   0.77 (0.48–1.23)  
Tumour-invasion depth
 T1 7 1.9 1 (reference) 0.010 na, because of the low number of events for T1 and T2 (T1–3 vs T4: 2.487 (1.53–4.04)) <0.001
 T2 18 4.8 0.65 (0.06–7.17)    
 T3 260 69.9 1.43 (0.20–10.34)    
 T4 87 23.4 2.78 (0.38–20.36)    
Lymph node involvement
 N0 156 41.9 1 (reference) <0.001 1 (reference) <0.001
 N1 142 38.2 1.47 (0.87–2.48)   1.25 (0.69–2.26)  
 N2 73 19.6 4.02 (2.42–6.69)   3.28 (1.85–5.83)  
 Unknown 1 0.3     
Tumour grade
 G1 23 6.2 1 (reference) 0.776 1 (reference) 0.092
 G2 240 64.5 1.39 (0.51–3.83)   0.78 (0.28–2.20)  
 G3 107 28.8 1.46 (0.51–4.16)   1.34 (0.47–3.83)  
 Unknown 2 0.5     
Tumour stage
 II 154 41.4 1 (reference) <0.001 1 (reference) 0.017
 III 217 58.3 2.36 (1.48–3.75)   1.86 (1.12–3.11)  
 Unknown 1 0.3     
Adjuvant chemotherapy
 No 141 37.9 1 (reference) 0.605 1 (reference) 0.181
 Yes 230 61.8 1.12 (0.73–1.72)   0.73 (0.73–1.72)  
 Unknown 1 0.3     
  1. Abbreviations: CI=confidence interval; HR=hazard ratio; na=not applicable; OS=overall survival; TTR=time to recurrence.